Phase 2 AMG 714 in Rheumatoid Arthritis - Full Text View

Sponsored by:	Amgen
Information provided by:	Amgen
ClinicalTrials.gov Identifier:	NCT00433875

Purpose

Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.

Condition	Intervention	Phase
Rheumatoid Arthritis	Drug: AMG 714	Phase II

MedlinePlus related topics: Rheumatoid Arthritis

Drug Information available for: Immunoglobulins Globulin, Immune

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Parallel Assignment
Official Title:	A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs

Further study details as provided by Amgen:

Estimated Enrollment:	180
Study Start Date:	December 2002

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria: Diagnosis of RA -

Exclusion Criteria: No prior biologic treatment for RA

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00433875

Sponsors and Collaborators

Amgen

Investigators

Study Director:

MD

Amgen

More Information

AmgenTrials clinical trials website This link exits the ClinicalTrials.gov site

Responsible Party:	Amgen Inc. ( Global Development Leader )
Study ID Numbers:	20030210
Study First Received:	February 8, 2007
Last Updated:	December 20, 2007
ClinicalTrials.gov Identifier:	NCT00433875
Health Authority:	Denmark: Ministry of Health; Germany: Federal Institute for Drugs and Medical Devices; Poland: Drug Institut; South Africa: Department of Health; Sweden: Medical Products Agency; United Kingdom: Medicines and Healthcare Products Regulatory Agency; United States: Food and Drug Administration

Study placed in the following topic categories:

Antibodies, Monoclonal
Antibodies
Autoimmune Diseases
Musculoskeletal Diseases
Joint Diseases

Arthritis
Connective Tissue Diseases
Arthritis, Rheumatoid
Rheumatic Diseases
Immunoglobulins

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009